ENDRA Life Sciences Inc.·4

Apr 7, 4:08 PM ET

Thornton Michael Milos 4

4 · ENDRA Life Sciences Inc. · Filed Apr 7, 2021

Insider Transaction Report

Form 4
Period: 2021-03-29
Thornton Michael Milos
Chief Technology Officer
Transactions
  • Award

    Stock Options

    2021-04-05+50,00050,000 total
    Exercise: $2.64Exp: 2031-04-05Common Stock (50,000 underlying)
  • Sale

    Common Stock

    2021-03-29$2.37/sh18,750$44,438274,960 total
  • Sale

    Common Stock

    2021-04-07$2.53/sh15,000$37,950259,960 total
Footnotes (4)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.39, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.56, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F4]This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION